🇺🇸 GLP-1 agonists in United States

17 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Weight Increased — 3 reports (17.65%)
  2. Abdominal Pain — 2 reports (11.76%)
  3. Back Pain — 2 reports (11.76%)
  4. Constipation — 2 reports (11.76%)
  5. Headache — 2 reports (11.76%)
  6. Product Dose Omission Issue — 2 reports (11.76%)
  7. Arterial Occlusive Disease — 1 report (5.88%)
  8. Arthralgia — 1 report (5.88%)
  9. Back Injury — 1 report (5.88%)
  10. Blood Cholesterol Abnormal — 1 report (5.88%)

Source database →

GLP-1 agonists in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is GLP-1 agonists approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for GLP-1 agonists in United States?

Medical College of Wisconsin is the originator. The local marketing authorisation holder may differ — check the official source linked above.